As a consequence, a phase III randomized trial specifically compared the four-drug combination with chemotherapy alone (cisplatin or carboplatin plus pemetrexed) in EGFR mutant or ALK translocated NSCLC that progressed after TKIs therapy and advantages in terms of response rates and PFS were reported in favor of the immunotherapy containing regimen (increasing as PDL-1 expression increased) but not in terms of OS [62]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.